Anti-Human Thymic Stromal Lymphopoietin (TSLP) (Tezepelumab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Thymic stromal lymphopoietin (TSLP) is a pleiotropic, epithelium-derived cytokine that ischaracterized as a lymphocyte growth factor1. TSLP plays a key role in the inflammatoryresponse of the lung, such as in asthma and COPD pathobiology. To function, TSLP engages aheteromeric complex of TSLP receptor chain and interleukin 7 receptor-α (IL-7Rα) to induceSTAT5. TSLP can be expressed as either a long or short isoform. It is the long isoform that isspecifically upregulated by inflammatory stimuli in human bronchial epithelial cells andmacrophages. In contrast, the short isoform is constitutively expressed in bronchial and colonicepithelial cells, lung fibroblasts, macrophages, and keratinocytes. TSLP mediates airwaystructural cell and immune cell interactions 2 . TSLP activity is upstream of the asthmainflammatory cycle making it an effective target for treatment. MEDI9929 (Tezepelumab) is a fully human monoclonal antibody developed for the treatment ofasthma, COPD, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, andeosinophilic esophagitis2. Tezepelumab inhibits the action of TSLP by blocking interaction withits receptor TSLPR. Tezepelumab reduces T2 inflammatory biomarkers, including airwayeosinophil counts, when administered in vivo3, 4, 5.

≥ 5.0 mg/ml

TSLP is mainly expressed by bronchial epithelial cells. TSLP alsoselectively localizes to the cytoplasm of human lung macrophages (HLM) and can be released byHLMs. Additionally, TSLP is expressed by human dendritic cells, airway smooth muscle cells, mast cells, monocytes, granulocytes, and fibroblasts.